Application and Research of Mesenchymal Stem Cells in Alleviating Severe Development of COVID-19 Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-28

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to evaluate the safety and efficacy of umbilical cord mesenchymal stem cells Therapy for COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)

NCT04288102

Corona Virus Disease 2019(COVID-19)

COMPLETED PHASE2

Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients

NCT06492798

Long COVID Post-Acute COVID-19 Syndrome

RECRUITING PHASE1/PHASE2

UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients With Refractory Hypoxia

NCT05689008

Mesenchymal Stem Cell COVID-19 Pneumonia

UNKNOWN PHASE3

Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients

NCT05132972

Covid 19

UNKNOWN PHASE2/PHASE3

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19

NCT05501418

COVID-19 Infection

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since 2019, novel coronavirus Disease 2019 (COVID-19) has spread and prevailed all over the world. COVID-19 has a wide range of clinical manifestations of respiratory and non-respiratory symptoms, including mild or severe influenza-like syndrome, respiratory distress or respiratory failure, and may end in multiple organ failure. Mesenchymal stem cells (MSCS) are considered as ideal seed cells for the treatment of various diseases due to their unique immune regulation, self-renewal and multiple differentiation potentials. The safety of MSC transplantation in the treatment of COVID-19 patients has been proved by a number of clinical studies, and has shown good clinical efficacy in shortening the course of the disease, alleviating lung damage, and reducing the level of inflammatory factors. However, previous clinical studies mainly focused on the efficacy of MSC transplantation in critically ill patients of COVID-19, ignoring the important role of cell transplantation in delaying or preventing COVID-19 's progress and preventing reinfection.COVID-19 has spread throughout the country and even the world, and the increase in severe and critical cases has caused a great impact on national medical and health resources. Stem cell transplantation offers new treatment ideas for COVID-19 patients. Since the role of cell transplantation in delaying or preventing the progression of light and medium novel coronavirus infection and preventing reinfection has not been clearly reported, this study intends to use MSC transplantation to evaluate the role of stem cells in the occurrence and development of novel coronavirus infection, so as to provide an important reference for the prevention and treatment of COVID-19 by MSC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MSCs group

Patient in Mscs group will receive MSCs implantation by intravenous injection Within 10-15 days of infection

Group Type EXPERIMENTAL

Umbilical cord mesenchymal stem cells implantation

Intervention Type BIOLOGICAL

Patient in Mscs group will receive MSCs implantation by intravenous injection.

comparator

Patients in comparator group will receive placebo treatment Within 10-15 days of infection

Group Type PLACEBO_COMPARATOR

Comparator

Intervention Type OTHER

Patients in comparator group will receive placebo treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Umbilical cord mesenchymal stem cells implantation

Patient in Mscs group will receive MSCs implantation by intravenous injection.

Intervention Type BIOLOGICAL

Comparator

Patients in comparator group will receive placebo treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-85 years;The diagnosis of COVID-19 infection was clinically classified as Moderate cases, and the criteria were based on Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia(Trial Version 10)
* Having the relevant clinical manifestations of COVID-19 infection.
* Having one or more of the following etiological and serological examination results
* Tested positive for Novel Coronavirus nucleic acid
* Tested positive for Novel Coronavirus antigen
* Novel Coronavirus was isolated and cultured positive
* Novel Coronavirus specific immunoglobulin G reaches a titration of at least 4-fold increase during convalescence compared with the acute phase.
* Moderate cases diagnostic criteria：Persistent high fever \> 3 days or (and) cough, Tachypnea etc，but respiratory rate≧30 breaths/ min ,oxygen saturation \> 93% on finger pulse oximeter taken at rest. Radiology shows the characteristic manifestations of COVID-19 pneumonia
* There are one or more of the following risk factors for the development of severe / critical severity:
* Patients over 65 years old, especially those who have not been vaccinated against novel coronavirus
* Patients with cardiovascular and cerebrovascular diseases (including hypertension), chronic lung disease, diabetes, chronic liver and kidney disease, tumors and other underlying diseases, as well as maintenance dialysis
* Patients with immune deficiency (such as AIDS, long-term use of corticosteroids or other immunosuppressive drugs resulting in immune dysfunction)
* Patients with Obesity (body mass index ≥30)
* late trimester of pregnancy and perinatal women
* Heavy smoker.

Exclusion Criteria

* Patients with prior or present tumor history,or precancerous lesions confirmed by pathological examination.
* Patients with active acute myocardial infarction or acute cerebral infarction.
* Pregnant or lactating patients.
* Patients with poorly controlled mental illness.
* Patients addicted to alcohol or drugs.
* Patients Unable or unwilling to sign informed consent or poor compliance.
* Patients with active tuberculosis or influenza virus, adenovirus and other acute respiratory virus infection.
* Patients deemed unsuitable for stem cell therapy by clinicians.
* Patients enrolled in other clinical trials within 3 months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Quanhai Li

Director of the Cell Therapy Laboratory

Responsibility Role PRINCIPAL_INVESTIGATOR